Due to its 99% specificity and sensitivity, the GENETWORx test is 99% accurate and delivers a significantly reduced risk of false negatives.

The FDA has acknowledged that the GENETWORx nasopharyngeal test meets the conditions outlined in the FDA Guidelines for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency for the allowable modifications to the CDC EUA, on March 26, 2020.

A healthcare provider or practice must administer GENETWORx’s nasopharyngeal test. Clients of GENETWORX receive their testing kits within 24 hours. The diagnostic test kit will include the nasopharyngeal swab and the universal transport media in a vial to ensure RNA and DNA survival.

Once the test is administered, the vial and test order are to be put in the provided bag and the prepaid FedEx package, which will be delivered right to a GENETWORx lab. GENETWORx has one of the fastest results-reporting platforms in the world, making results available in less than 72 hours. These results can be accessed by the patient or the provider in the online portal, as well as via text or phone, or our COVID-19 software solution, named Aura.

Aura users have expedited turnaround times of COVID-19 test results, as this end-to-end digital management system significantly reduces laboratory process time. Aura ensures a compliant, safe, healthy population for healthcare providers, schools, universities, governments, cities, employers, and more. Learn more about the benefits of this software.